JP2017086084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017086084A5 JP2017086084A5 JP2017017360A JP2017017360A JP2017086084A5 JP 2017086084 A5 JP2017086084 A5 JP 2017086084A5 JP 2017017360 A JP2017017360 A JP 2017017360A JP 2017017360 A JP2017017360 A JP 2017017360A JP 2017086084 A5 JP2017086084 A5 JP 2017086084A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- human
- mouse
- antibody
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 32
- 238000003780 insertion Methods 0.000 claims description 22
- 230000037431 insertion Effects 0.000 claims description 22
- 230000000977 initiatory effect Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims 27
- 241000699666 Mus <mouse, genus> Species 0.000 claims 19
- 108020004414 DNA Proteins 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 230000003053 immunization Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 108091092195 Intron Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019197622A JP6930695B2 (ja) | 2009-07-08 | 2019-10-30 | 動物モデルおよび治療用分子 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22396009P | 2009-07-08 | 2009-07-08 | |
| GBGB0911846.4A GB0911846D0 (en) | 2009-07-08 | 2009-07-08 | Animal models and therapeutic molecules |
| US61/223,960 | 2009-07-08 | ||
| GB0911846.4 | 2009-07-08 | ||
| GB0913102A GB0913102D0 (en) | 2009-07-28 | 2009-07-28 | Animal models and therapeutic molesules |
| GB0913102.0 | 2009-07-28 | ||
| US35566610P | 2010-06-17 | 2010-06-17 | |
| US61/355,666 | 2010-06-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022430A Division JP6088562B2 (ja) | 2009-07-08 | 2015-02-06 | 動物モデルおよび治療用分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019197622A Division JP6930695B2 (ja) | 2009-07-08 | 2019-10-30 | 動物モデルおよび治療用分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017086084A JP2017086084A (ja) | 2017-05-25 |
| JP2017086084A5 true JP2017086084A5 (https=) | 2019-07-04 |
| JP6612275B2 JP6612275B2 (ja) | 2019-11-27 |
Family
ID=43428834
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519063A Active JP5944312B2 (ja) | 2009-07-08 | 2010-07-07 | 動物モデルおよび治療用分子 |
| JP2015022430A Active JP6088562B2 (ja) | 2009-07-08 | 2015-02-06 | 動物モデルおよび治療用分子 |
| JP2017017360A Active JP6612275B2 (ja) | 2009-07-08 | 2017-02-02 | 動物モデルおよび治療用分子 |
| JP2019197622A Active JP6930695B2 (ja) | 2009-07-08 | 2019-10-30 | 動物モデルおよび治療用分子 |
| JP2020102976A Active JP6876853B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
| JP2020102978A Expired - Fee Related JP6876854B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
| JP2020102977A Active JP7141427B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519063A Active JP5944312B2 (ja) | 2009-07-08 | 2010-07-07 | 動物モデルおよび治療用分子 |
| JP2015022430A Active JP6088562B2 (ja) | 2009-07-08 | 2015-02-06 | 動物モデルおよび治療用分子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019197622A Active JP6930695B2 (ja) | 2009-07-08 | 2019-10-30 | 動物モデルおよび治療用分子 |
| JP2020102976A Active JP6876853B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
| JP2020102978A Expired - Fee Related JP6876854B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
| JP2020102977A Active JP7141427B2 (ja) | 2009-07-08 | 2020-06-15 | 動物モデルおよび治療用分子 |
Country Status (22)
| Country | Link |
|---|---|
| US (33) | US20120204278A1 (https=) |
| EP (19) | EP2517557B2 (https=) |
| JP (7) | JP5944312B2 (https=) |
| KR (1) | KR101875233B1 (https=) |
| CN (2) | CN102638971B (https=) |
| AU (4) | AU2010269978B2 (https=) |
| BR (1) | BR112012000536A2 (https=) |
| CA (1) | CA2767436A1 (https=) |
| CY (1) | CY1126083T1 (https=) |
| DK (12) | DK3241435T3 (https=) |
| ES (10) | ES2884309T3 (https=) |
| HR (2) | HRP20130253T1 (https=) |
| HU (2) | HUE061788T2 (https=) |
| LT (1) | LT3241435T (https=) |
| NO (1) | NO2792236T3 (https=) |
| NZ (1) | NZ597481A (https=) |
| PL (4) | PL2564695T3 (https=) |
| PT (4) | PT2564695E (https=) |
| SG (2) | SG2014010995A (https=) |
| SI (2) | SI2421357T1 (https=) |
| SM (1) | SMT201300046B (https=) |
| WO (1) | WO2011004192A1 (https=) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP2346994B1 (en) | 2008-09-30 | 2022-02-16 | Ablexis, LLC | Knock-in mice for the production of chimeric antibodies |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| KR102203727B1 (ko) | 2010-03-31 | 2021-01-18 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| AU2011266843C9 (en) * | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
| US9012717B2 (en) | 2010-06-22 | 2015-04-21 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| JP6482757B2 (ja) | 2010-07-26 | 2019-03-13 | トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． | トランスジェニック動物および使用方法 |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| RU2722373C2 (ru) | 2011-02-25 | 2020-05-29 | Редженерон Фармасьютикалс, Инк. | Мыши adam6 |
| KR20190107761A (ko) | 2011-03-09 | 2019-09-20 | 셀 시그널링 테크놀러지, 인크. | 모노클로날 항체를 생성하는 방법 및 시약 |
| EP2739300B1 (en) | 2011-07-05 | 2019-06-19 | Duke University | N-terminal deleted gp120 immunogens |
| RS59728B1 (sr) * | 2011-08-05 | 2020-02-28 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| GB2501753A (en) * | 2012-05-04 | 2013-11-06 | Kymab Ltd | Human antibodies |
| BR112014006394A2 (pt) * | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
| CA2850745C (en) | 2011-10-03 | 2022-12-13 | Duke University | Vaccine |
| KR20160098514A (ko) * | 2011-10-17 | 2016-08-18 | 리제너론 파아마슈티컬스, 인크. | 제한된 면역글로불린 중쇄 마우스 |
| LT3424947T (lt) * | 2011-10-28 | 2021-03-10 | Regeneron Pharmaceuticals, Inc. | Genetiškai modifikuotos t ląstelių receptorių pelės |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SI2770821T1 (en) * | 2011-10-28 | 2018-01-31 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex of mice |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| DK3590332T3 (da) | 2011-10-28 | 2022-05-23 | Regeneron Pharma | Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler |
| US20180295821A1 (en) * | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| RU2664181C2 (ru) * | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
| RS62023B1 (sr) * | 2012-02-01 | 2021-07-30 | Regeneron Pharma | Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene |
| IN2014DN08163A (https=) * | 2012-03-06 | 2015-05-01 | Regeneron Pharma | |
| KR102228296B1 (ko) | 2012-03-16 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물 |
| SG10201700360VA (en) | 2012-03-16 | 2017-03-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| MX2014011047A (es) | 2012-03-16 | 2015-04-08 | Regeneron Pharma | Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph. |
| JP2015512635A (ja) | 2012-03-28 | 2015-04-30 | カイマブ・リミテッド | クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物 |
| GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| PT3597037T (pt) * | 2012-06-12 | 2021-06-01 | Regeneron Pharma | Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito |
| KR102159163B1 (ko) | 2012-08-03 | 2020-09-23 | 에스에이비, 엘엘씨 | 유전자삽입 동물에서 인간 항체의 제조를 위한 복합 염색체 조작 |
| HRP20231356T1 (hr) * | 2012-12-14 | 2024-02-16 | Omniab, Inc. | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže |
| KR20150115775A (ko) * | 2013-02-06 | 2015-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 동물을 이용한 b 세포 계통 기반의 면역원 설계 |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| EP2840892B1 (en) | 2013-02-20 | 2018-04-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| PL2958937T3 (pl) | 2013-02-22 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| EP3418379B1 (en) | 2013-09-18 | 2020-12-09 | Kymab Limited | Methods, cells & organisms |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| KR102276752B1 (ko) | 2014-03-21 | 2021-07-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| RS60359B1 (sr) * | 2014-06-06 | 2020-07-31 | Regeneron Pharma | Postupci i kompozicije za modifikovanje ciljanog lokusa |
| EP3169778B1 (en) | 2014-07-14 | 2023-10-25 | Washington State University | Nanos knock-out that ablates germline cells |
| CA2959428A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| GB201418713D0 (en) | 2014-10-21 | 2014-12-03 | Kymab Ltd | Bindings Proteins |
| EP3222718A4 (en) * | 2014-11-20 | 2018-05-30 | Kyoto University | Method for knock-in of dna into target region of mammalian genome, and cell |
| MX2017011194A (es) | 2015-03-03 | 2018-04-10 | Kymab Ltd | Anticuerpos, usos y métodos. |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CN113349159B (zh) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | 非人动物中的人源化t细胞介导的免疫应答 |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3384030A4 (en) | 2015-12-03 | 2019-07-03 | Trianni, Inc. | IMPROVED IMMUNOGLULINIVITY |
| AU2017213633B2 (en) | 2016-02-04 | 2023-08-03 | Trianni, Inc. | Enhanced production of immunoglobulins |
| PL3426271T3 (pl) | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| IL323024A (en) | 2016-05-20 | 2025-10-01 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide RNAs |
| HUE061619T2 (hu) | 2016-06-03 | 2023-07-28 | Regeneron Pharma | Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018128691A1 (en) * | 2016-11-04 | 2018-07-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| SI3558369T1 (sl) * | 2016-12-21 | 2025-06-30 | Cephalon Llc | Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba |
| NZ755816A (en) | 2017-01-19 | 2026-03-27 | Omniab Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| EP3574017A1 (en) | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg antibodies |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| BR112019016989A2 (pt) | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| GB2561352B (en) * | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| KR20200038490A (ko) * | 2017-08-01 | 2020-04-13 | 시티 오브 호프 | 항-il1rap 항체 |
| MX2020004063A (es) | 2017-10-20 | 2020-10-05 | Hutchinson Fred Cancer Res | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. |
| DK4140297T3 (da) | 2017-12-05 | 2025-06-23 | Regeneron Pharma | Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| CN108486125B (zh) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在制备人源单域抗体中的应用 |
| CN108486126A (zh) | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在人源化抗体中的应用 |
| DK3773713T3 (da) | 2018-04-06 | 2025-08-18 | Regeneron Pharma | Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| GB2576914A (en) * | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| GB201820687D0 (en) | 2018-12-19 | 2019-01-30 | Kymab Ltd | Antagonists |
| EP3927832A4 (en) | 2019-02-18 | 2022-11-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS |
| EP3952999A4 (en) | 2019-04-09 | 2023-01-25 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| SG11202111258TA (en) * | 2019-06-05 | 2021-11-29 | Regeneron Pharma | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| WO2021105389A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
| JP7726881B2 (ja) | 2019-12-02 | 2025-08-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
| KR20230018439A (ko) | 2020-06-02 | 2023-02-07 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물 |
| KR20230024822A (ko) * | 2020-06-25 | 2023-02-21 | 주식회사 휴맵 | 이형접합성 형질전환 동물 |
| CA3187680A1 (en) | 2020-09-11 | 2022-03-17 | Yashu Liu | Identification and production of antigen-specific antibodies |
| KR20230084157A (ko) | 2020-10-08 | 2023-06-12 | 주식회사 휴맵 | 인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법 |
| CA3204101A1 (en) * | 2020-12-09 | 2022-06-16 | Trianni, Inc. | Heavy chain-only antibodies |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| MX2024001277A (es) | 2021-07-26 | 2024-02-15 | Abcuro Inc | Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1). |
| WO2023097236A1 (en) * | 2021-11-24 | 2023-06-01 | The Rockefeller University | Compositions and methods for generating immunoglobulin knock-in mice |
| GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
| EP4512243A1 (en) | 2023-08-21 | 2025-02-26 | Kymab Limited | Binding molecules |
| CN120035380A (zh) * | 2023-09-15 | 2025-05-23 | 赛业（苏州）生物科技有限公司 | 用于制备抗体的基因修饰小鼠及其制备方法 |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
| WO2025166904A1 (zh) * | 2024-02-07 | 2025-08-14 | 赛业（苏州）生物科技有限公司 | 用于制备抗体的基因修饰小鼠及其制备方法 |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
| WO2026072990A1 (en) | 2024-09-27 | 2026-04-02 | Abcuro, Inc. | Methods of treating t-cell large granular lymphocytic leukemia |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US114985A (en) * | 1871-05-16 | Improvement in apparatus for cooling and preserving milk and other liquids | ||
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| US4720449A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
| US5565321A (en) | 1993-01-22 | 1996-10-15 | Immunex Corporation | Detection of mutations in a CD40 ligand gene |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| DE4331162A1 (de) | 1993-09-14 | 1995-03-16 | Bayer Ag | Verfahren zur Herstellung von Cyaninfarbstoffen |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU3507297A (en) | 1996-06-26 | 1998-01-14 | Baylor College Of Medicine | Chromosomal rearrangement by insertion of two recombination substrates |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US20020088019A1 (en) | 1997-09-02 | 2002-07-04 | Oron Yacoby-Zeevi | Methods of and pharmaceutical compositions for improving implantation of embryos |
| US6187994B1 (en) | 1997-11-18 | 2001-02-13 | Pioneer Hi-Bred International, Inc. | Compositions and methods for genetic modification of plants |
| AU752105B2 (en) | 1997-12-05 | 2002-09-05 | Europaisches Laboratorium Fur Molekularbiologie (Embl) | Novel dna cloning method |
| EP0939120A1 (en) | 1998-02-27 | 1999-09-01 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| JP2003503015A (ja) | 1999-05-03 | 2003-01-28 | メダレツクス・インコーポレーテツド | スタフィロコッカス・アウレウスに対するヒト抗体 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US6355412B1 (en) | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2307503A1 (en) * | 2000-05-02 | 2001-11-02 | Carlos F. Barbas Iii | Peptides for use as a vaccine or treatment for hiv infection |
| CA2416701A1 (en) * | 2000-07-21 | 2002-01-31 | The United States Of America, As Represented By The Secretary Of Agricul Ture | Methods for the replacement, translocation and stacking of dna in eukaryotic genomes |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
| DE60144305D1 (de) | 2000-11-17 | 2011-05-05 | Kyowa Hakko Kirin Co Ltd | Expression von xenogenen (humanen) Immunglobulinen in klonierten, transgenen Huftieren |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| EP1409646B1 (en) * | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| AUPR446701A0 (en) * | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
| JP2003000243A (ja) | 2001-06-25 | 2003-01-07 | Takachika Azuma | 変異体の製造法 |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| AU2002331077A1 (en) | 2001-08-13 | 2003-03-03 | Amberwave Systems Corporation | Dram trench capacitor and method of making the same |
| US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
| US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
| US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| WO2003061363A2 (en) | 2002-01-17 | 2003-07-31 | Albert Einstein College Of Medicine Of Yeshiva University | Mutations caused by activation-induced cytidine deaminase |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CA2496233A1 (en) | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| WO2004030623A2 (en) * | 2002-10-01 | 2004-04-15 | Mitos Pharmaceuticals, Inc. | Nitroxide radioprotector formulations and methods of use |
| US7700356B2 (en) * | 2002-11-08 | 2010-04-20 | The United States Of America As Represented By The Secretary Of Agriculture | System for gene targeting and producing stable genomic transgene insertions |
| DE10251918A1 (de) * | 2002-11-08 | 2004-05-19 | Horn, Carsten, Dipl.-Biochem. Dr. | Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen |
| CL2003002461A1 (es) | 2002-11-27 | 2005-01-07 | Dow Chemical Company Agroscien | Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas. |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| CN1326878C (zh) * | 2003-04-29 | 2007-07-18 | 中国抗体制药有限公司 | 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用 |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
| US7205148B2 (en) | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
| GB2403475B (en) * | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
| EP1644417B1 (en) * | 2003-07-15 | 2014-04-30 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
| US7604994B2 (en) | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
| US7205140B2 (en) | 2003-10-20 | 2007-04-17 | Campusgen Gmbh | Nucleotide sequence for creatinine deiminase and method of use |
| RS53984B1 (sr) | 2003-12-10 | 2015-10-30 | E. R. Squibb & Sons L.L.C. | Ip-10 antitela i njihove upotrebe |
| WO2005092926A2 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
| US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| FR2875239B1 (fr) | 2004-09-10 | 2007-07-20 | Inst Necker Ass Loi De 1901 | Procede pour l'acceleration des mutations somatiques et son application en proteomique |
| CN101076542A (zh) | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
| WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
| AU2005295269B2 (en) † | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| US20080184380A1 (en) * | 2004-10-22 | 2008-07-31 | Therapeutic Human Polyclonals Inc. | Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals |
| WO2006055704A2 (en) | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
| BRPI0519596B1 (pt) | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| JP2008538912A (ja) * | 2005-04-29 | 2008-11-13 | イナート・ファルマ | 遺伝子導入動物および組換え抗体の製造方法 |
| CN101297031B (zh) | 2005-05-14 | 2013-06-05 | 复旦大学 | 在脊椎动物中作为遗传操作和分析工具的piggyBac |
| EP1780272A1 (en) | 2005-10-27 | 2007-05-02 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method for enhancing somatic hypermutation, gene conversion and class switch recombination |
| GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
| TWI404727B (zh) * | 2006-01-25 | 2013-08-11 | 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 | 對偶基因排除 |
| US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
| AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US7709257B2 (en) | 2006-06-27 | 2010-05-04 | Vax Design Corp. | Models for vaccine assessment |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP2061812A4 (en) | 2006-08-22 | 2010-06-09 | G2 Inflammation Pty Ltd | METHOD FOR THE PRODUCTION OF ANTIBODIES |
| US7778624B2 (en) * | 2006-09-01 | 2010-08-17 | Wanda Ying Li | Outdoor umbrella with audio system |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| JP5642972B2 (ja) | 2007-02-21 | 2014-12-17 | ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用 |
| BRPI0809435A2 (pt) | 2007-03-27 | 2014-09-09 | Sea Lane Biotechnologies, Llc | Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos |
| GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| NZ583019A (en) | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| WO2009097006A2 (en) | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
| JP5642549B2 (ja) * | 2007-10-12 | 2014-12-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 複数の核酸からのタンパク質発現 |
| CA2708776A1 (en) | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
| US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP2252659A2 (en) | 2008-01-25 | 2010-11-24 | Cabot Corporation | Method of preparing modified colored pigments |
| KR101409375B1 (ko) | 2008-01-31 | 2014-06-18 | 삼성전자주식회사 | 반도체 메모리장치의 블록 디코딩 회로 |
| US20110107445A1 (en) | 2008-03-26 | 2011-05-05 | Iti Scotland Limited | Efficient Insertion of DNA Into Embryonic Stem Cells |
| WO2009129247A2 (en) | 2008-04-14 | 2009-10-22 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| ES2436044T3 (es) * | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| EP2346994B1 (en) * | 2008-09-30 | 2022-02-16 | Ablexis, LLC | Knock-in mice for the production of chimeric antibodies |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
| WO2010091182A2 (en) | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
| JP2012518398A (ja) | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 抗原結合性構築物 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| CN102482639B (zh) | 2009-04-03 | 2016-01-06 | 医学研究会 | 活化诱导胞苷脱氨酶(aid)突变体及使用方法 |
| KR101829073B1 (ko) | 2009-06-26 | 2018-02-13 | 아이2 파마슈티컬스, 인크. | 대리 경쇄의 발현 |
| BR112012000536A2 (pt) * | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| GB0911846D0 (en) | 2009-07-08 | 2009-08-19 | Genome Res Ltd | Animal models and therapeutic molecules |
| GB0913102D0 (en) | 2009-07-28 | 2009-09-02 | Genome Res Ltd | Animal models and therapeutic molesules |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| JP5781508B2 (ja) | 2009-07-15 | 2015-09-24 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を産生させるための手段および方法 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US8592644B2 (en) | 2009-08-13 | 2013-11-26 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal CDRS |
| WO2011056864A1 (en) | 2009-11-05 | 2011-05-12 | Anaptysbio, Inc. | Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation |
| US20120233715A1 (en) | 2009-11-17 | 2012-09-13 | Kyowa Hakko Kirin Co., Ltd | Human artificial chromosome vector |
| EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| US8754287B2 (en) | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| AU2011266843C9 (en) | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
| US9012717B2 (en) | 2010-06-22 | 2015-04-21 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
| SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| KR20130118925A (ko) | 2010-12-22 | 2013-10-30 | 제넨테크, 인크. | 항-pcsk9 항체 및 사용 방법 |
| RU2722373C2 (ru) | 2011-02-25 | 2020-05-29 | Редженерон Фармасьютикалс, Инк. | Мыши adam6 |
| RS59728B1 (sr) | 2011-08-05 | 2020-02-28 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| KR20160098514A (ko) | 2011-10-17 | 2016-08-18 | 리제너론 파아마슈티컬스, 인크. | 제한된 면역글로불린 중쇄 마우스 |
| US20130102031A1 (en) | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US20180295821A1 (en) | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| RU2664181C2 (ru) | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
| RS62023B1 (sr) | 2012-02-01 | 2021-07-30 | Regeneron Pharma | Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene |
| HK1200463A1 (en) | 2012-03-02 | 2015-08-07 | 瑞泽恩制药公司 | Human antibodies to clostridium difficile toxins |
| IN2014DN08163A (https=) | 2012-03-06 | 2015-05-01 | Regeneron Pharma | |
| MX2014011047A (es) | 2012-03-16 | 2015-04-08 | Regeneron Pharma | Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph. |
| JP2015512635A (ja) | 2012-03-28 | 2015-04-30 | カイマブ・リミテッド | クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物 |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US8518765B1 (en) | 2012-06-05 | 2013-08-27 | Intermolecular, Inc. | Aqua regia and hydrogen peroxide HCl combination to remove Ni and NiPt residues |
| PT3597037T (pt) | 2012-06-12 | 2021-06-01 | Regeneron Pharma | Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| US9938538B2 (en) | 2012-11-09 | 2018-04-10 | Shenzhen Institute Of Molecular Crop Design | Fertility gene and use thereof |
| DK2931897T3 (en) | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
| EP2840892B1 (en) | 2013-02-20 | 2018-04-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
| US9783618B2 (en) * | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US20140331344A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Ltd. | Transgenic Animals |
| US20140331339A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Limited | Transgenic Non-Human Assay Vertebrates, Assays and Kits |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| JP7087648B2 (ja) * | 2018-05-08 | 2022-06-21 | トヨタ自動車株式会社 | 電池パック |
-
2010
- 2010-07-07 BR BR112012000536-7A patent/BR112012000536A2/pt not_active Application Discontinuation
- 2010-07-07 KR KR1020127003297A patent/KR101875233B1/ko active Active
- 2010-07-07 EP EP12171793.8A patent/EP2517557B2/en active Active
- 2010-07-07 EP EP16151215.7A patent/EP3028565B1/en not_active Revoked
- 2010-07-07 NO NO14176740A patent/NO2792236T3/no unknown
- 2010-07-07 ES ES17174426T patent/ES2884309T3/es active Active
- 2010-07-07 PT PT121949705T patent/PT2564695E/pt unknown
- 2010-07-07 EP EP19207053.0A patent/EP3622815B1/en active Active
- 2010-07-07 AU AU2010269978A patent/AU2010269978B2/en active Active
- 2010-07-07 PL PL12194970T patent/PL2564695T3/pl unknown
- 2010-07-07 CN CN201080040055.5A patent/CN102638971B/zh active Active
- 2010-07-07 EP EP20120195041 patent/EP2604111A3/en not_active Withdrawn
- 2010-07-07 DK DK17174426.1T patent/DK3241435T3/da active
- 2010-07-07 EP EP21169074.8A patent/EP3888457B1/en active Active
- 2010-07-07 EP EP12171791.2A patent/EP2517556B2/en active Active
- 2010-07-07 SI SI201030177T patent/SI2421357T1/sl unknown
- 2010-07-07 DK DK10734546.4T patent/DK2421357T3/da active
- 2010-07-07 ES ES21169074T patent/ES2978496T3/es active Active
- 2010-07-07 CN CN201510587176.6A patent/CN105340834B/zh active Active
- 2010-07-07 DK DK16151214.0T patent/DK3028564T5/da active
- 2010-07-07 PT PT171744261T patent/PT3241435T/pt unknown
- 2010-07-07 DK DK19207053.0T patent/DK3622815T3/da active
- 2010-07-07 DK DK12171791.2T patent/DK2517556T4/da active
- 2010-07-07 PT PT107345464T patent/PT2421357E/pt unknown
- 2010-07-07 NZ NZ597481A patent/NZ597481A/xx unknown
- 2010-07-07 HU HUE19207053A patent/HUE061788T2/hu unknown
- 2010-07-07 HR HRP20130253AT patent/HRP20130253T1/hr unknown
- 2010-07-07 EP EP23161385.2A patent/EP4215043A1/en active Pending
- 2010-07-07 ES ES19207053T patent/ES2948572T3/es active Active
- 2010-07-07 EP EP12194977.0A patent/EP2604110B1/en not_active Revoked
- 2010-07-07 ES ES10734546T patent/ES2403087T3/es active Active
- 2010-07-07 DK DK16151215.7T patent/DK3028565T3/da active
- 2010-07-07 CA CA2767436A patent/CA2767436A1/en active Pending
- 2010-07-07 DK DK12171793.8T patent/DK2517557T4/da active
- 2010-07-07 SG SG2014010995A patent/SG2014010995A/en unknown
- 2010-07-07 EP EP16151214.0A patent/EP3028564B2/en active Active
- 2010-07-07 HU HUE17174426A patent/HUE055817T2/hu unknown
- 2010-07-07 ES ES21169076T patent/ES2993214T3/es active Active
- 2010-07-07 DK DK14170196.1T patent/DK2798950T4/da active
- 2010-07-07 EP EP14170196.1A patent/EP2798950B2/en active Active
- 2010-07-07 EP EP21169072.2A patent/EP3871497B1/en active Active
- 2010-07-07 DK DK14176740.0T patent/DK2792236T4/da active
- 2010-07-07 ES ES22155461T patent/ES2994445T3/es active Active
- 2010-07-07 WO PCT/GB2010/051122 patent/WO2011004192A1/en not_active Ceased
- 2010-07-07 ES ES19207052T patent/ES2965212T3/es active Active
- 2010-07-07 SG SG2011096427A patent/SG177380A1/en unknown
- 2010-07-07 PL PL17174426T patent/PL3241435T3/pl unknown
- 2010-07-07 DK DK19207050.6T patent/DK3622813T4/da active
- 2010-07-07 ES ES12194970.5T patent/ES2537239T3/es active Active
- 2010-07-07 ES ES21169072T patent/ES2974417T3/es active Active
- 2010-07-07 EP EP19207050.6A patent/EP3622813B2/en active Active
- 2010-07-07 EP EP21169076.3A patent/EP3871498B1/en active Active
- 2010-07-07 EP EP19207052.2A patent/EP3622814B1/en active Active
- 2010-07-07 PT PT121717912T patent/PT2517556E/pt unknown
- 2010-07-07 LT LTEP17174426.1T patent/LT3241435T/lt unknown
- 2010-07-07 JP JP2012519063A patent/JP5944312B2/ja active Active
- 2010-07-07 PL PL10734546T patent/PL2421357T3/pl unknown
- 2010-07-07 DK DK12194977.0T patent/DK2604110T3/en active
- 2010-07-07 ES ES12171791.2T patent/ES2557737T3/es active Active
- 2010-07-07 EP EP22155461.1A patent/EP4014729B1/en active Active
- 2010-07-07 EP EP14176740.0A patent/EP2792236B2/en active Active
- 2010-07-07 SI SI201032086T patent/SI3241435T1/sl unknown
- 2010-07-07 EP EP20100734546 patent/EP2421357B1/en not_active Revoked
- 2010-07-07 PL PL12171791T patent/PL2517556T3/pl unknown
- 2010-07-07 DK DK12194970.5T patent/DK2564695T3/en active
- 2010-07-07 EP EP20120194970 patent/EP2564695B1/en not_active Revoked
- 2010-07-07 EP EP17174426.1A patent/EP3241435B1/en active Active
-
2011
- 2011-12-02 US US13/310,431 patent/US20120204278A1/en not_active Abandoned
-
2012
- 2012-03-09 US US13/416,684 patent/US9447177B2/en active Active
-
2013
- 2013-01-14 US US13/740,727 patent/US9505827B2/en active Active
- 2013-04-23 SM SM201300046T patent/SMT201300046B/xx unknown
- 2013-09-27 US US14/040,405 patent/US20140201856A1/en not_active Abandoned
- 2013-09-27 US US14/040,427 patent/US20140201854A1/en not_active Abandoned
- 2013-10-17 US US14/056,707 patent/US20140150126A1/en not_active Abandoned
- 2013-10-17 US US14/056,700 patent/US11812731B2/en active Active
- 2013-10-17 US US14/056,434 patent/US20140182003A1/en not_active Abandoned
- 2013-11-14 US US14/080,630 patent/US10165763B2/en active Active
- 2013-12-20 US US14/137,902 patent/US9434782B2/en active Active
-
2014
- 2014-09-25 US US14/497,054 patent/US20150113669A1/en not_active Abandoned
- 2014-10-16 US US14/516,461 patent/US10064398B2/en active Active
-
2015
- 2015-02-06 JP JP2015022430A patent/JP6088562B2/ja active Active
- 2015-06-25 US US14/750,870 patent/US20160044900A1/en not_active Abandoned
- 2015-08-04 US US14/818,162 patent/US11564380B2/en active Active
-
2016
- 2016-02-04 US US15/016,211 patent/US20160150768A1/en not_active Abandoned
- 2016-07-20 US US15/214,963 patent/US20160345551A1/en not_active Abandoned
- 2016-08-09 US US15/232,122 patent/US11606941B2/en active Active
- 2016-08-30 US US15/251,969 patent/US20170051045A1/en not_active Abandoned
- 2016-10-14 AU AU2016244326A patent/AU2016244326B2/en active Active
- 2016-11-23 US US15/360,502 patent/US20170071174A1/en not_active Abandoned
- 2016-12-19 US US15/383,188 patent/US20170101482A1/en not_active Abandoned
- 2016-12-19 US US15/383,101 patent/US20170099815A1/en not_active Abandoned
- 2016-12-19 US US15/383,353 patent/US20170094956A1/en not_active Abandoned
- 2016-12-19 US US15/383,342 patent/US20170099816A1/en not_active Abandoned
- 2016-12-20 US US15/385,372 patent/US20170105396A1/en not_active Abandoned
- 2016-12-20 US US15/385,348 patent/US20170099817A1/en not_active Abandoned
-
2017
- 2017-02-02 JP JP2017017360A patent/JP6612275B2/ja active Active
-
2018
- 2018-07-17 AU AU2018206729A patent/AU2018206729C1/en active Active
-
2019
- 2019-10-30 JP JP2019197622A patent/JP6930695B2/ja active Active
-
2020
- 2020-05-08 US US16/870,413 patent/US20200375158A1/en not_active Abandoned
- 2020-05-08 US US16/870,365 patent/US20200352144A1/en not_active Abandoned
- 2020-06-15 JP JP2020102976A patent/JP6876853B2/ja active Active
- 2020-06-15 JP JP2020102978A patent/JP6876854B2/ja not_active Expired - Fee Related
- 2020-06-15 JP JP2020102977A patent/JP7141427B2/ja active Active
- 2020-06-18 US US16/905,557 patent/US20200352145A1/en not_active Abandoned
- 2020-06-18 US US16/905,537 patent/US20200337280A1/en active Pending
-
2021
- 2021-01-07 AU AU2021200079A patent/AU2021200079B2/en active Active
- 2021-08-04 HR HRP20211253TT patent/HRP20211253T1/hr unknown
-
2022
- 2022-09-13 US US17/943,533 patent/US20240057572A1/en not_active Abandoned
- 2022-11-29 US US18/059,809 patent/US20230270088A1/en not_active Abandoned
-
2023
- 2023-01-31 US US18/162,043 patent/US20230225302A1/en active Pending
- 2023-02-09 US US18/166,813 patent/US20230263143A1/en not_active Abandoned
- 2023-07-05 CY CY20231100315T patent/CY1126083T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017086084A5 (https=) | ||
| JP7141427B2 (ja) | 動物モデルおよび治療用分子 | |
| CN105695415A (zh) | 动物模型及治疗分子 | |
| TR201905992T4 (tr) | Bir insan değişken bölgeli bir immünoglobülin hibrit hafif zincir ifade eden fareler. | |
| JP2015502149A5 (https=) | ||
| MXPA03008454A (es) | Animales transgenicos que expresan anticuerpos especificos para genes de interes y usos de los mismos. | |
| CN117587070B (zh) | 一种经遗传修饰的非人哺乳动物的制备方法及应用 | |
| EP4346396A1 (en) | Animal models and therapeutic molecules | |
| AU2023286840A1 (en) | Animal models and therapeutic molecules | |
| HK40060958B (en) | Rodent models and therapeutic molecules | |
| HK40058708B (en) | Rodent models and therapeutic molecules | |
| HK40058709B (en) | Rodent models and therapeutic antibodies | |
| CN120583884A (zh) | 人免疫球蛋白重链长cdr3转基因构建体及其用途 | |
| HK40014986B (en) | Animal models and therapeutic molecules | |
| HK40014992B (en) | Animal models and therapeutic molecules | |
| HK40014992A (en) | Animal models and therapeutic molecules |